Press release
Pancreatic Cancer Pipeline Drugs Review H1 2017
For More on Pancreatic Cancer Pipeline Review H1 2017 report inquire @ https://tinyurl.com/Pancreatic-Cancer-Pipeline .
Report Description:
Pharmaceutical guide Pancreatic Cancer - Pipeline Review H1 2017 guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type and reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.
The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Get Discount on Report@ https://tinyurl.com/Pancreatic-Cancer-Therapeutics .
Report Includes Pancreatic Cancer Pipeline by Companies:
3-V Biosciences Inc, 4P-Pharma SAS, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Actuate Therapeutics Inc, Adamed Sp z oo, Aduro BioTech Inc, Advanced Cancer Therapeutics LLC, Advantagene Inc, Agenus Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alissa Pharma, Allinky Biopharma, Almac Discovery Ltd, Altor BioScience Corp, Ambrx Inc, amcure GmbH, American Gene Technologies International Inc, Amgen Inc, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Aphios Corp, APIM Therapeutics AS, Apogenix GmbH, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, Autotelic Inc, AVEO Pharmaceuticals Inc, Axcentua Pharmaceuticals AB, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene (Beijing) Co Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio ASA, Beta Pharma Inc, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, BioLineRx Ltd, Biomar Microbial Technologies, Biomunex Pharmaceuticals, Bioncotech Therapeutics SL, Bionomics Ltd, BioNTech AG, Biotest AG, Biouniversa srl, BLR Bio LLC, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd, Calithera Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Cantargia AB, Cascadian Therapeutics Inc, Cavion LLC, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celleron Therapeutics Ltd, Cellular Biomedicine Group Inc, Celprogen Inc, Celyad SA, Centrose LLC, Ceronco Biosciences, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology Inc, COARE Biotechnology Inc, Codiak BioSciences Inc, Concordia International Corp, Confluence Life Sciences Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, Cytori Therapeutics Inc, CytRx Corp, CyTuVax BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, DEKK-TEC Inc, Denceptor Therapeutics Ltd, Diffusion Pharmaceuticals Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endor Nanotechnologies SL, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, FibroGen Inc, Formosa Laboratories Inc, Forty Seven Inc, Fountain Biopharma Inc, Fujifilm Corp, Fusion Antibodies Ltd, Galena Biopharma Inc, GamaMabs Pharma SA, Geistlich Pharma AG, Genelux Corp, Genentech Inc, Genisphere LLC, Genmab A/S, Gilead Sciences Inc, GlaxoSmithKline Plc, Globeimmune Inc, GlycoMimetics Inc, Glycotope GmbH, Golden Biotechnology Corp, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, Helix BioPharma Corp, Horizon Pharma Plc, Humorigin Biotechnology Corp, iCeutica Inc, Idera Pharmaceuticals Inc, Igenica Biotherapeutics Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune Pharmaceuticals Inc, Immune System Key Ltd, Immune Therapeutics Inc, Immunitor Inc, Immunomedics Inc, Immunotope Inc, Immunovo BV, Immupharma Plc, Incyte Corp, Inflection Biosciences Ltd, Innopharmax Inc, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Intezyne Technologies Inc, Inventiva, InvivoGen Therapeutics, Io Therapeutics Inc, Ipsen SA, ISU ABXIS Co Ltd, Jasco Pharmaceuticals LLC, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kalyra Pharmaceuticals Inc, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics Inc, Keystone Nano Inc, Komipharm International Co Ltd, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Lidds AB, Lion Biotechnologies Inc, Lipopharma Therapeutics SL, Lixte Biotechnology Holdings Inc, Loxo Oncology Inc, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, Mebiopharm Co Ltd, MediaPharma Srl, Medicenna Therapeutics Corp, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Millennium Pharmaceuticals Inc, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, Mount Tam Biotechnologies Inc, NanoCarrier Co Ltd, NantKwest Inc, Nascent Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, NBE-Therapeutics AG, Nerviano Medical Sciences Srl, NewLink Genetics Corp, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Novogen Ltd, Novus Therapeutics Inc, Noxxon Pharma AG, NuCana BioMed Ltd, OBI Pharma Inc, Omeros Corp, Oncodesign SA, Oncolytics Biotech Inc, Oncomatryx Biopharma SL, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, Orega Biotech SAS, Oribase Pharma, Oryx GmbH & Co KG, Patrys Ltd, Pfizer Inc, Pharma Two B Ltd, PharmAbcine Inc, PharmaCyte Biotech Inc, Pharmedartis GmbH, Phoenix Biotechnology Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Prima BioMed Ltd, Propanac Biopharma Inc, Provectus Biopharmaceuticals Inc, Puretech Health plc, Quest PharmaTech Inc, Quimatryx SL, Quintessence Biosciences Inc, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Samumed LLC, Samyang Holdings Corp, Sanofi, Sareum Holdings Plc, SATT North SAS, Selecta Biosciences Inc, Sierra Oncology Inc, SignPath Pharma Inc, Sillajen Biotherapeutics, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Spring Bank Pharmaceuticals Inc, Stelic Institute & Co Inc, Strongbridge Biopharma plc, Sumitomo Dainippon Pharma Co Ltd, Sun BioPharma Inc, Sun Pharma Advanced Research Company Ltd, Sunshine Biopharma Inc, Swedish Orphan Biovitrum AB, Symic Biomedical Inc, Symphogen A/S, SynCore Biotechnology Co Ltd, Synergys Biotherapeutics Inc, Synovo GmbH, SyntheX Inc, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takara Bio Inc, Takeda Pharmaceutical Company Ltd, Takis Srl, Targovax ASA, Tarveda Therapeutics Inc, tella Inc, Threshold Pharmaceuticals Inc, Tiltan Pharma Ltd, Tocagen Inc, Tolero Pharmaceuticals Inc, Transcriptogen Ltd, Transgene SA, TVAX Biomedical Inc, Tyg Oncology Ltd, Tyme Technologies Inc, Tyrogenex Inc, UbiVac LLC, ValiRx Plc, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, Vaximm AG, Vaxon Biotech, VCN Biosciences SL, Vect-Horus SAS, Verastem Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, ViiV Healthcare Ltd, Viralytics Ltd, Virobay Inc, ViroStatics srl, Wilex AG, Zeria Pharmaceutical Co Ltd.
Scope:
-The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology).
Purchase This Report at: https://tinyurl.com/Pancreatic-Cancer-Drugs .
Major Table of Content:
• Introduction
• Pancreatic Cancer - Overview
• Pancreatic Cancer - Therapeutics Development
• Pancreatic Cancer - Therapeutics Assessment
• Pancreatic Cancer - Companies Involved in Therapeutics Development
• Pancreatic Cancer - Drug Profiles
• Pancreatic Cancer - Dormant Projects
• Pancreatic Cancer - Discontinued Products
• Pancreatic Cancer - Product Development Milestones.
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@reportsnreports.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Pipeline Drugs Review H1 2017 here
News-ID: 612618 • Views: …
More Releases from ReportsandReports
The Growing Importance of Smart Wearable Equipment - Global Market: Today's Worl …
The report presents detailed information regarding the prominent players and potential competitors in the Smart Wearable Equipment - Global market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses…
Vegetable Glycerin - Global Market 2023 Driving Factors Forecast Research 2029
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Vegetable Glycerin - Global market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role…
Underground Concrete - Global Market Booming Worldwide with Latest Trend and Fut …
The report presents detailed information regarding the prominent players and potential competitors in the Underground Concrete - Global market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses revenue,…
Eucalyptol - Global Market was Led by the Solution Category
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Eucalyptol - Global market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role in…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
